Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > FY 2020 Audited Financial Statement.
View:
Post by Biggainer on Apr 28, 2021 12:46pm

FY 2020 Audited Financial Statement.

Any thoughts?
Comment by Biggainer on Apr 28, 2021 12:48pm
https://www.accesswire.com/642698/Theralase-Release-FY2020-Audited-Financial-Statements
Comment by SouthernTierTom on Apr 28, 2021 12:58pm
I say we bank the corners BIGBeecher ; - ) ....  I see you're "on assignment"  at SQD.V Aren't they another University Health Network "under-achiever" Good thing for MMED they are an independent early stage LSD company... They would NEVER reach a value of 2.5 BILLION CAD with the weight of a world-class medical institution..."weighing them down? When ...more  
Comment by Biggainer on Apr 28, 2021 1:17pm
Getting destroyed on SQD (down 33%) as well as TLT (my biggest holding, down 39%). ACB is the only green (up 13%). I need a multiple bagger stock to get me out of the red, any tips anyone?
Comment by Oden6570 on Apr 28, 2021 1:26pm
Datametrex DM. V
Comment by lesflics on Apr 28, 2021 1:30pm
VentriPoint Diagnostics Ltd V.VPT
Comment by Eoganacht on Apr 28, 2021 12:53pm
MD&A page 14: "As of December 31, 2020, the Company has cash and cash equivalents of $7,880,243 and as a result the Company believes that it will be able to continue as a going concern for at least 12 months from the date of these audited consolidated financial statements."
Comment by riverrrow on Apr 28, 2021 1:07pm
If TLT isn't trading at $1 by year end there won't be any point in continuing to own shares. At $1 a share a financing of 10 million shares will not be dilutive and will finance the company through the end of 2022. GLTA.
Comment by O12009 on Apr 28, 2021 1:14pm
  They may get all the money they need from warrants exercised 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250